Clinical Trial Update: Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating durvalumab (MEDI4736) in combination with total neoadjuvant therapy for locally advanced rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN